ImmunoPrecise Antibodies Reschedules Q3 Fiscal 2025 Financial Results Amid AI-Powered Antibody Discovery Progress
Curated by THEOUTPOST
On Wed, 12 Mar, 8:03 AM UTC
2 Sources
2 Sources
[1]
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data accurately reflects the Company's value and complies with all regulatory requirements. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, March 28, 2025, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. ***Participant Dial-In Details*** Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. Anyone listening to the call is encouraged to read the company's periodic reports available on the company's profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family").
[2]
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 By Investing.com
The Company to host an earnings conference call via webcast AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (IPA or the Company), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data accurately reflects the Company's value and complies with all regulatory requirements. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, March 28, 2025, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. Participant Dial-In Details Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. Anyone listening to the call is encouraged to read the company's periodic reports available on the company's profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). View source version on businesswire.com: https://www.businesswire.com/news/home/20250311018829/en/
Share
Share
Copy Link
ImmunoPrecise Antibodies Ltd., a leader in AI-powered antibody discovery, has rescheduled its Q3 Fiscal 2025 financial results release to March 28, 2025, allowing auditors more time for valuation reviews.
ImmunoPrecise Antibodies Reschedules Financial Results Release
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a global leader in AI-powered antibody discovery and development, has announced a rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally slated for March 13, 2025, the new release date has been set for Friday, March 28, 2025 12.
Reasons for Rescheduling
The company has cited the need for additional time to allow its auditors to complete necessary reviews and audit requirements, particularly focusing on valuation calculations of goodwill and intangible assets. This extension is aimed at ensuring that the financial data accurately reflects the company's value and complies with all regulatory requirements 12.
Conference Call and Webcast Details
IPA will host a live conference call and webcast to discuss the results and provide a corporate update on the new release date, March 28, 2025, at 10:30 AM Eastern Time. The conference call will be accessible via webcast, with a replay option available through a link provided in the Events section of the company's IR pages 12.
Participant Information
Participants are advised to call one of the allocated dial-in numbers and provide either the Conference ID 3224490 or Conference Name to the operator. It is recommended that callers join the conference five minutes prior to the start time to allow for registration 12.
Company Overview
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through proprietary and patented technologies. The company specializes in the development of therapeutic antibodies and is known for addressing complex industry challenges 12.
AI and Technology Focus
IPA's use of AI in antibody discovery and development positions it at the intersection of biotechnology and artificial intelligence. The company's integrated end-to-end suite of capabilities supports the entire process of therapeutic antibody development, showcasing the growing role of AI in advancing medical research and drug discovery 12.
Global Presence
The IPA Family includes several subsidiaries across North America and Europe, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V. This global presence underscores the company's international scope in the field of AI-powered antibody research and development 12.
Investor Relations and Transparency
The company encourages investors and interested parties to review its periodic reports available on www.sedarplus.com and www.sec.gov. These reports include discussions of risk factors, historical results of operations, and financial conditions, promoting transparency and informed decision-making among stakeholders 12.
Reference
[1]
ImmunoPrecise Antibodies Reschedules Financial Results and Business Highlights Report
ImmunoPrecise Antibodies Ltd. announces the rescheduling of its financial results and recent business highlights report for the fourth quarter and fiscal year-end 2024. The company cites the need for additional time to complete its year-end audit procedures.
2 Sources
2 Sources
ImmunoPrecise Secures $30 Million Financing Agreement with Yorkville Advisors Global LP
ImmunoPrecise Antibodies Ltd. has entered into a financing agreement with Yorkville Advisors Global LP for up to $30 million in convertible debentures. This move aims to strengthen the company's financial position and support its growth initiatives.
2 Sources
2 Sources
ImmunoPrecise Antibodies Advances Anti-Aging Research with Mayo Clinic, Leveraging AI Technology
ImmunoPrecise Antibodies Ltd. contributes to groundbreaking Mayo Clinic study on mitochondrial dysfunction in aging, using AI-driven technology and proprietary antibody platform to tap into the $81 billion anti-aging market.
2 Sources
2 Sources
Spectral AI Announces Q4 and Full Year 2024 Financial Results Conference Call
Spectral AI, developer of the AI-driven DeepView® System for burn healing prediction, schedules its Q4 and full year 2024 financial results conference call for March 27, 2025.
2 Sources
2 Sources
Spectral AI Announces Q3 2024 Financial Results Conference Call
Spectral AI, an AI company focused on medical diagnostics in wound care, has scheduled its 2024 third quarter financial results and conference call for November 6, 2024.
2 Sources
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved